# Veracyte Shares Fall 56% After Updating 2026 Revenue Outlook

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/50753
Published: 2026-11-07T10:39:47.000Z
Updated: 2026-11-07T10:39:47.000Z
Section: Business

> The stock fell $29.18 to $23.34 in the final half-hour of Thursday’s trading.

Veracyte shares fell 56% Thursday, Nov. 5, after the cancer-focused molecular diagnostics company released third-quarter results and updated its 2026 revenue outlook, with shares sliding $29.18 late in the session.

The stock reached $23.34 during the final half-hour of trading. Veracyte is a global molecular diagnostics company focused on cancer care, and its shares trade on Nasdaq under the ticker VCYT.